273-97-2

Usage

Uses

Used in Pharmaceutical Industry:
Oxazolo[4,5-b]pyridine is used as a potential anti-cancer agent for its ability to target and potentially treat various types of cancer. Its unique structure allows it to interact with biological targets, making it a subject of interest for the development of new cancer therapies.
Used in Neurological Applications:
In the treatment of neurological disorders, Oxazolo[4,5-b]pyridine is utilized for its potential to modulate specific pathways or receptors involved in these conditions, offering a new avenue for therapeutic intervention.
Used in Antimicrobial Applications:
Oxazolo[4,5-b]pyridine is employed as an antimicrobial agent, leveraging its capacity to combat microbial infections. Its chemical properties allow it to target and inhibit the growth of various microorganisms, contributing to the development of new antimicrobial drugs.
Used in Anti-inflammatory Applications:
As an anti-inflammatory agent, Oxazolo[4,5-b]pyridine is used to reduce inflammation, a common characteristic of many diseases and conditions. Its potential to modulate inflammatory responses makes it a candidate for the treatment of inflammatory disorders.
Each of these applications underscores the versatility and potential of Oxazolo[4,5-b]pyridine in advancing modern medicine, with ongoing research aimed at harnessing its properties for the benefit of patients.

Upstream product

• 16867-03-1 2-amino-3-hydroxypyridine 
• 122-51-0 orthoformic acid triethyl ester 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 52333-71-8 2-pyridyl-2-yl[1,3]oxazolo[4,5-b]pyridine 
• 52333-44-5 2-phenyl[1,3]oxazolo[4,5-b]pyridine 
• 52333-45-6 2-(4-chlorophenyl)[1,3]oxazolo[4,5-b]pyridine 
• 52333-87-6 2-(4-methylphenyl)[1,3]oxazolo[4,5-b]pyridine 
• 52333-46-7 2-(4-methoxyphenyl)[1,3]oxazolo[4,5-b]pyridine 
• 95331-56-9 4-[1,3]oxazolo[4,5-b]pyridin-2-ylaniline 
• 1189168-00-0 8-(benzyloxy)-5-chloro-7-[1,3]oxazolo[4,5-b]pyridin-2-ylquinoline 
• 1276038-50-6 C₂₈H₁₄F₆N₄O₃ 
• 1447734-44-2 C₂₇H₁₅F₃N₄O₃ 

Relevant academic research and scientific papers

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis

A whole organism high-throughput screen of approximately 87,000 compounds against Trypanosoma brucei brucei led to the recent discovery of several novel compound classes with low micromolar activity against this organism and without appreciable cytotoxici

1,3-Dibromo-5,5-dimethylhydantoin as an efficient homogeneous catalyst for synthesis of benzoxazoles, benzimidazoles, and oxazolo[4,5-b]pyridines

A simple and highly efficient method for synthesis of benzoxazoles, benzimidazoles, and oxazolo[4,5-b]pyridines is described. Condensation of orthoesters with o-substituted anilines or 2-amino-3-hydroxypyridine was performed in the presence of catalytic amounts of commercially available, inexpensive, and moisture-stable 1,3-dibromo-5,5-dimethylhydantoin under solvent-free conditions. The corresponding heterocycles were obtained in good to excellent yields. The main advantages of the present procedure are mild reaction conditions, short reaction times, high yields of products, easy work-up, and absence of solvent. Graphical abstract: [Figure not available: see fulltext.]

Copper-catalyzed direct oxidative C-H amination of benzoxazoles with formamides or secondary amines under mild conditions

A facile, efficient, and practical method for copper-catalyzed direct C-H amination of benzoxazoles with formamides or secondary amines has been developed. The system can be performed in the absence of external base and only requires O2 or even air as oxidant. A variety of substituted benzoxazol-2-amines were synthesized with moderate to excellent yield.

Mild and efficient synthesis of benzoxazoles, benzothiazoles, benzimidazoles, and oxazolo[4,5-b]pyridines catalyzed by Bi(III) salts under solvent-free conditions

A series of benzoxazoles, benzothiazoles, benzimidazoles, and oxazolo[4,5-b]pyridines was efficiently synthesized from the reactions of o-aminophenols, o-aminothiophenol, o-phenylenediamines, and 2-amino-3- hydroxypyridine with orthoesters in the presence of catalytic amounts of Bi(III) salts, such as Bi(TFA)3, Bi(OTf)3, and BiOClO4 ? xH2O under solvent-free conditions. The remarkable features of this new protocol are high conversion, very short reaction times, cleaner reaction profiles under solvent-free conditions, straightforward procedure, and use of relatively non-toxic catalysts. Springer-Verlag 2007.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in p

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.

Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof

The present invention is directed to a novel process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents that are useful in the synthesis of a variety of pharmaceuticals, in particular certain cysteine protease inhibitors.

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu